Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 5Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Post-transplant Lymphoproliferative Disease 1Plasmacytoma 1Lymphoma, Non-Hodgkin 1Leukemia 1Hodgkin Disease 1

Interventions

Cyclophosphamide 12Etoposide 10Doxorubicin 9Brentuximab Vedotin 8fludarabine phosphate 7Vinblastine 7Dacarbazine 7Bleomycin 7Vincristine 6Melphalan 6camrelizumab 5Radiotherapy 5Nivolumab 5Mycophenolic Acid 5Decitabine 5pembrolizumab 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Gemcitabine 4Filgrastim 4Cytarabine 4Cyclosporine 4Busulfan 4Bendamustine Hydrochloride 4ABVD protocol 4Tacrolimus 3Prednisone 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Ifosfamide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hodgkin Disease × Leukapheresis × Clear all
NCT04665063 2020-12-29

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
20 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡